Insulin resistance in type 2 diabetes: Role of fatty acids

Diabetes/Metabolism Research and Reviews

Volumn 18, Issue SUPPL. 2, 2002, Pages

  Arner, Peter ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adipose tissue; Free fatty acids; Lipolysis; Liver; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBUMIN; ANTIDIABETIC AGENT; FATTY ACID; FIBRINOGEN; GLUCOSE; GLUCOSE TRANSPORTER 4; GLYCEROL; GLYCOGEN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HORMONE; INSULIN; INSULIN RECEPTOR; LIPID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROSTAGLANDIN; PROTEIN; TRIACYLGLYCEROL;

ADIPOSE TISSUE; ARTICLE; BLOOD GLUCOSE MONITORING; CARDIOVASCULAR DISEASE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DIABETIC OBESITY; DISEASE COURSE; DISEASE PREDISPOSITION; DRUG CLASSIFICATION; DYSLIPIDEMIA; FATTY ACID METABOLISM; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; LIVER; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PORTAL VEIN; PRIORITY JOURNAL; RISK FACTOR; SKELETAL MUSCLE;

DIABETES MELLITUS, TYPE 2; FATTY ACIDS, NONESTERIFIED; HUMANS; INSULIN RESISTANCE;

EID: 0036254607     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.254     Document Type: Article

References (30)

1. Banting lecture 1988. Role of insulin resistance in human disease
2. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial
3. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients
4. Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus
5. Diabetes mellitus: A differential into insulin-sensitive and insulin-insensitive types
6. Metabolic factors that affect beta-cell function and survival
7. Insulin resistance implications for type II diabetes mellitus and coronary heart disease
8. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS)
9. Risk profile of macrovascular disease in diabetes mellitus
10. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population
11. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study
12. Insulin-resistance syndrome and cardiovascular complications of non-insulin-dependent diabetes mellitus
13. Resistance to insulin-mediated glucose disposal as a predictor of cardiovascular disease
14. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: Results from two population studies in Finland
15. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations
16. Insulin resistance and coronary artery disease
17. Asymptomatic atherosclerosis and insulin resistance
18. Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance
19. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance
20. Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance
21. Regulation of lipolysis in humans. Pathophysiological modulation in obesity, diabetes, and hyperlipidaemia
22. Regulation of lipolysis in fat cells
23. Free fatty acids-the link between obesity and insulin resistance
24. Insulin resistance directly correlates with increased saturated fatty acids in skeletal muscle triglycerides
25. Roles of PPARs in health and disease
26. Are increased plasma non-esterified fatty acid concentrations a risk marker for coronary heart disease and other chronic diseases?
27. Regulatory interactions between lipids and carbohydrates: The glucose fatty acid cycle after 35 years
28. Not all fat is alike
29. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
30. Thiazolidinediones: A new class of antidiabetic drug